Navigation Links
Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting

ich appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the U.S. or Europe.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The ris
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014   Unique ... Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, ... distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based ... According to the agreement, US-based Larasan will work ... 6" frozen pizza through Larasan,s vast distribution network ...
(Date:7/30/2014)... 2014 Silicon Valley Bank, the bank of ... that examines the merger, acquisition and IPO activity ... to the annual report based on 2013 data, venture ... SVB started tracking the data in 2005. ... solid healthcare M&A activity over the last few years, ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Fourth - Quarter 2010 Highlights ... Gross profit increased by 5.8% over Q4 FY09 to $8.8 ... $3.1 million with EPS of $0.13 Full Fiscal ... $115.0 million Gross Profit increased 23.7% YOY to $34.6 million ...
... Otonomy, Inc . announced today that David A. Weber, ... of the Board of Directors. Jay Lichter, Ph.D., managing director of ... continue to actively support the company as a member of the ... Dr. Weber to the Otonomy team, as his extensive experience in ...
Cached Medicine Technology:Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 2Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 3Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 4Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 5Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 6Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 7Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 8Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 9Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 10Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 11Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 12Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 13Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 14Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early ... like most people, in 2008 he suffered extreme financial hardship ... way, Paul carefully studied the difference between people who have ... Based on the knowledge he acquired, he was able to ... and health, but also grow his clients' personal and financial ...
(Date:7/30/2014)... , Resistance to artemisinin, the main drug to ... among the Plasmodium falciparum ( P. ... is likely caused by a genetic mutation in ... combination therapyas opposed to a standard three-day coursehas ... according to findings published today in the ...
(Date:7/30/2014)... Volunteers from the Church of Scientology ... this summer with massive distribution of Truth About ... these volunteers on Strøget, the famous Copenhagen walking street. ... shopping and its ambiance, some quarter of a million ... day. , These activities are part of a ...
(Date:7/30/2014)... July 30, 2014 Visitors to our ... over $8,500 to ensure its protection. Bob Kiesendahl, one ... check to the Delaware Highlands Conservancy for donations collected ... small $2-per-stay donations add up fast, as visitors welcome ... Upper Delaware River Region. , The Kiesendahl family has ...
(Date:7/30/2014)... A new network of 25 regional stroke centers and ... StrokeNet) is working to change the way stroke ... of the last two decades, stroke remains a major ... disability for 795,000 Americans. The numbers are expected to ... , To accelerate the pace of progress, NIH StrokeNet ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... www.deo.ucsf.edu , has been launched by the University of California, ... successful American Diabetes Association (ADA) accredited teaching program curriculum created by ... the past 30 years. , ... SAN FRANCISCO ...
... Successful And Effective Campaign Could Help Prevent,Another Blood Crisis, ... Just Six Coaches, Orlando Has 35!!!, NEW YORK, ... a dangerous blood emergency, New York City Councilman Eric ... and,Investigation, and representatives of New York Blood Center called ...
... Findley Davies announced today,the hiring of Tod ... Charlotte,Office effective August 1, 2008. He will be ... Benefits Practice in North Carolina and,surrounding areas. Tod ... as a Health and Welfare consultant for a ...
... new report on severe sporting injuries among high school ... a larger proportion of all such injuries than previously ... of North Carolina at Chapel Hill-based National Center for ... for 65.1 percent of all catastrophic sports injuries among ...
... Aug. 11 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, announced today that it will,present ... Financial Equity,Conference which will be held Monday, August ... Lake Las Vegas Resort, Nevada. Barry G. Caldwell,President ...
... Consumables Revenue Up 15% Year over Year ... Gross Profit Margin of 77%, HAYWARD, ... non-invasive tissue tightening in the aesthetic,industry, today reported its financial results for ... of 2008 totaled $17.9 million, an,increase of 2% from $17.5 million for ...
Cached Medicine News:Health News: 80 Million Americans Can Benefit from New Diabetes Resource : Free Educational Website Created by UCSF Diabetes Teaching Center Goes Live 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 3Health News:UNC study: Two-thirds of severe sports injuries to female students due to cheerleading 2Health News:STAAR Surgical to Present at the Noble Financial Equity Conference 2Health News:Thermage Announces Second Quarter 2008 Financial Results 2Health News:Thermage Announces Second Quarter 2008 Financial Results 3Health News:Thermage Announces Second Quarter 2008 Financial Results 4Health News:Thermage Announces Second Quarter 2008 Financial Results 5Health News:Thermage Announces Second Quarter 2008 Financial Results 6Health News:Thermage Announces Second Quarter 2008 Financial Results 7Health News:Thermage Announces Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 9
Molteno3 Glaucoma Drainage Device incorporates the latest advances from Professor Moltenos glaucoma research. It has been extensively tested since early 2004 and gives even better control of intraocu...
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
Medicine Products: